SPYRE THERAPEUTICS INC (SYRE:NASDAQ)
$106.65 0.16 (0.1502%)
Analysed SPYRE THERAPEUTICS INC (SYRE:NASDAQ) News Sources
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
24-08-2026
yahoo.com
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
24-08-2026
yahoo.com
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential
04-06-2026
yahoo.com
Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)
24-06-2026
advfn.com
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
29-06-2026
yahoo.com
Spyre Therapeutics Announces Grants of Inducement Awards
02-07-2026
yahoo.com
A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know
06-08-2026
fool.com
Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know
06-08-2026
fool.com
Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data?
10-08-2026
yahoo.com
This Stock’s Already Up Nearly 600% Over the Past Year
19-08-2026
barchart.com
What is the current price of SPYRE THERAPEUTICS INC (SYRE:NASDAQ)?
The current price of SPYRE THERAPEUTICS INC (SYRE:NASDAQ) is $106.65.
SPYRE THERAPEUTICS INC (SYRE:NASDAQ) absolute price change since previous trading day?
The absolute price change of SPYRE THERAPEUTICS INC (SYRE:NASDAQ) since the previous trading day is $0.16.
SPYRE THERAPEUTICS INC (SYRE:NASDAQ) percentage price change since previous trading day?
The percentage price change of SPYRE THERAPEUTICS INC (SYRE:NASDAQ) since the previous trading day is 0.1502%.
What is the most recent average sentiment score for SPYRE THERAPEUTICS INC (SYRE:NASDAQ)?
The most recent average sentiment score for SPYRE THERAPEUTICS INC (SYRE:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for SPYRE THERAPEUTICS INC (SYRE:NASDAQ)?
The most recent sentiment for SPYRE THERAPEUTICS INC (SYRE:NASDAQ) is .
SEC-8K** Filing Available For SPYRE THERAPEUTICS INC (SYRE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.